Artificial intelligence (AI) voice agents helped older adults with high blood pressure to accurately report their blood pressure readings and improved blood pressure management, according to preliminary research presented at…
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality worldwide, despite advances in guideline-directed medical therapy. Novel or adjunctive pharmacologic interventions are continuously explored…
A new study published in the journal of BMC Diabetology and Metabolic Syndrome revealed that the risk of developing type 2 diabetes mellitus (T2DM) was 5-times greater for women with…
Medication errors and adverse drug events pose a significant risk for pediatric patients undergoing anesthesia, especially in lower middle-income countries (LMICs) where healthcare systems face resource constraints. A recent study…
A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults living with obesity, including those with type 2 diabetes (T2D), according…
UK: Researchers have found in a new study that sleep-disordered breathing (SDB) is highly prevalent in hypertrophic cardiomyopathy (HCM) patients and is linked to adverse myocardial remodeling, greater diastolic dysfunction,…
China: A new study has found that metabolic syndrome (MS) independently contributes to more severe and unfavorable coronary artery plaque characteristics in patients with type 2 diabetes mellitus (T2DM). These…
China: A new cardiac MRI–based workflow has shown promise in improving the prediction of sudden cardiac death (SCD) among individuals with nonischemic dilated cardiomyopathy (DCM), offering clinicians refined tools for…
USA: Researchers have found in a new cost-effectiveness analysis that vasectomy is a more cost-effective permanent contraceptive option. While salpingectomy prevented more unintended pregnancies and reduced ovarian cancer risk, it…
China: Patients with type 2 diabetes (T2D) face a substantially higher risk of developing severe metabolic dysfunction-associated steatotic liver disease (MASLD) and major adverse liver outcomes (MALO). However, this risk…